Midwife Licensure Exam High-Risk Pregnancy & Complications (Recognize & Refer) — Postpartum ComplicationsStudy Notes

Understanding normal postpartum recovery is essential because deviations from this pattern signal complications. Involution is the systematic reduction of the uterus and reproductive organs to their pre-pregnancy state over approximately 6 weeks. **Fundal Involution (Uterine Contraction):** Immediately after delivery, the fundus is firm and palpable at or just below the umbilicus. The uterus then regresses at a predictable rate: approximately one fingerbreadth (1 cm) per day. By postpartum day 10, the fundus becomes non-palpable above the pubic symphysis. This descent is dependent on adequate uterine contraction and the absence of retained placental tissue. **Lochia (Postpartum Vaginal Discharge):** Lochia progresses through three predictable stages, each lasting approximately 3–10 days, though total duration extends to 6 weeks: - Lochia Rubra (Days 1–3): Dark red, heavy flow (1–2 pads per hour is normal), contains blood, mucosa, and tissue. Clots up to the size of a plum are acceptable. - Lochia Serosa (Days 4–10): Pinkish-brown to brownish-red, lighter flow. Contains less blood and more white blood cells and epithelial cells. - Lochia Alba (Weeks 2–6): Yellowish-white, scant flow. Contains primarily white blood cells, decidual cells, and epithelial tissue. **Critical Assessment Finding:** Any foul odor in lochia at any stage is abnormal and suggests infection. A return to bright-red (rubra-like) bleeding after progression to serosa or alba is a red flag for complications such as subinvolution or retained products. **Cervical, Vaginal, and Perineal Changes:** The cervix rapidly closes but remains open until approximately day 10 (allowing bacteria ascent if intact). The vagina gradually returns to pre-pregnancy tone; perineal lacerations heal through inflammatory, proliferative, and remodeling phases. Edema and bruising typically resolve within the first week. Understanding normal healing helps nurses distinguish between expected swelling and pathological hematoma formation.

Postpartum hemorrhage is the leading cause of maternal death globally and in the Philippines, making it a critical competency for NLE success. The definition varies by delivery route but is unified by the concept of hemodynamic instability. **Definition and Classification:** Postpartum hemorrhage is defined as: - Blood loss exceeding 500 mL after vaginal delivery - Blood loss exceeding 1,000 mL after cesarean delivery - Any blood loss causing hemodynamic instability (tachycardia, hypotension, altered mental status, decreased urine output) PPH is classified by timing: - **Early (Primary) PPH:** Occurs within 24 hours postpartum. Accounts for ~80% of PPH cases. Most frequently caused by uterine atony. - **Late (Secondary) PPH:** Occurs from 24 hours to 6–12 weeks postpartum. Usually due to retained placental fragments, subinvolution (delayed involution), or infection. **The 4 Ts Mnemonic for PPH Etiology:** 1. **Tone (Uterine Atony) — The Most Common Cause:** The uterus fails to contract adequately after placental delivery, leaving dilated vessels open and promoting continued bleeding. The uterus feels boggy (soft, enlarged, poorly contracted) rather than firm. Atony accounts for 50–60% of PPH cases. Risk factors for uterine atony include: - Overdistension: macrosomia (large baby), multiple gestation (twins/triplets), polyhydramnios (excess amniotic fluid) - Labor abnormalities: prolonged labor, precipitous labor, use of oxytocin for augmentation - Maternal factors: high parity (multiparity increases risk), advanced maternal age - Placental factors: retained placenta, placental abnormalities - Uterine factors: previous PPH, uterine fibroids, uterine anomalies 2. **Trauma (Genital Tract Lacerations and Hematomas):** Bleeding from lacerations of the vagina, cervix, perineum, or rectum. Suspect trauma when bleeding is bright red and steady despite a firm, well-contracted fundus. Hematomas (blood collections within the genital tract) form when vessels bleed into the tissue spaces. Risk factors include: - Instrumental delivery (forceps, vacuum extraction) - Precipitous labor and delivery - Episiotomy - Nulliparity (first-time mothers have less tissue elasticity) - Macrosomia - Operative vaginal delivery 3. **Tissue (Retained Placental Products):** Incomplete placental expulsion or retained placental fragments prevent full uterine contraction, perpetuating bleeding. Fragments maintain the placental site open, preventing vessel compression. Risk factors include: - Placental abnormalities (placenta accreta, increta, percreta—especially with prior cesarean) - Manual removal of placenta - Infection/chorioamnionitis - Succenturiate lobe (accessory lobe) - Assisted delivery 4. **Thrombin (Coagulation Disorders):** Inherent or acquired coagulopathies prevent clot formation and stabilization. Disseminated intravascular coagulation (DIC) is the most concerning postpartum coagulation disorder; it consumes platelets and clotting factors faster than they can be replaced, leading to paradoxical thrombosis and bleeding. Causes of postpartum coagulopathy include: - DIC (triggered by placental abruption, sepsis, amniotic fluid embolism, acute fatty liver of pregnancy) - Thrombocytopenia (immune, drug-induced) - Von Willebrand disease or factor deficiencies - Massive transfusion (dilutional coagulopathy) - Use of anticoagulants in pregnancy **Clinical Assessment for PPH:** **Vital Signs and Shock Indicators:** Progress through shock stages: - Class 1 (Compensated): <15% blood volume loss (~750 mL); vital signs may be normal; mother is anxious or restless - Class 2 (Early Decompensation): 15–30% loss (~1,500 mL); tachycardia (>100 bpm), tachypnea (>20 breaths/min), narrowed pulse pressure - Class 3 (Progressive): 30–40% loss; marked tachycardia, hypotension (systolic BP <100), confusion, cool skin, oliguria - Class 4 (Irreversible): >40% loss; severe hypotension, profound bradycardia, loss of consciousness **Key Point:** Vital sign changes often lag behind blood loss; restlessness and anxiety may be the earliest sign of hypovolemia. Never reassure based on "normal" blood pressure alone. **Fundal Assessment:** - A **firm, contracted fundus** rules out uterine atony. If bleeding persists with a firm fundus, suspect trauma or coagulopathy. - A **boggy, soft uterus** indicates atony. The fundus may be higher than expected (not descended appropriately). - A **fundus deviated to one side** (classically to the right) is a pathognomonic sign of a **full bladder.** A distended bladder mechanically prevents uterine contraction by displacing the uterus upward and laterally. Emptying the bladder immediately allows fundal contraction and control of bleeding. **Lochia Assessment:** - Estimate blood loss: count and weigh pads (1 mL blood weighs approximately 1 gram; a fully saturated pad contains ~5–10 mL) - Color and consistency: bright red bleeding with large clots may suggest ongoing bleeding; dark red with normal progression is reassuring - Presence of foul odor: suggests infection **Perform Bimanual Compression (If Indicated):** For suspected uterine atony unresponsive to massage, insert one hand into the vagina and place the other on the abdomen, squeezing the uterus between the two hands. This manually compresses the uterus and tamponades bleeding while medications take effect. This is a temporary measure while planning definitive treatment. **Priority Nursing Interventions for PPH (in order of priority):** 1. **Call for Help and Alert the Obstetrician Immediately:** PPH is a medical emergency requiring rapid response. Activate your facility's emergency protocol. In Philippine rural settings (Barangay Health Stations, Rural Health Units), initiate immediate referral to a capable facility. 2. **Ensure Patent Airway and Adequate Oxygenation:** - Position the mother supine with a slightly elevated left hip (to relieve aortocaval compression if needed) - Apply supplemental oxygen at 8–10 L/min via non-rebreather mask to maintain oxygen saturation >94% - Keep NPO (nothing by mouth) in case emergency surgery becomes necessary 3. **Establish/Maintain Large-Bore IV Access:** - Insert two 18-gauge or larger IV cannulas - Draw blood for type and crossmatch, complete blood count (CBC), coagulation studies (PT/INR, aPTT, fibrinogen, D-dimer), and blood cultures if infection is suspected - Begin rapid crystalloid infusion (Normal Saline 0.9% or Lactated Ringer's); use warmed fluids and prepare for massive transfusion protocol 4. **Assess and Manage the Fundus:** - **If the fundus is boggy/soft:** Perform fundal massage in a circular motion with firm pressure for 30 seconds to 1 minute. Continue until the uterus feels firm. Fundal massage often initiates strong uterine contractions. - **If the fundus is deviated to the side:** Have the mother void spontaneously or insert a urinary catheter to empty the bladder immediately. Reassess the fundus; it should firm and descend as the bladder empties. - **If the fundus is firm but bleeding persists:** Suspect trauma or coagulopathy. Inspect the perineum, vagina, and cervix for lacerations. Prepare for examination under anesthesia and possible repair. 5. **Administer Uterotonic Medications (if ordered):** - See detailed pharmacology section below - These medications cause sustained uterine contraction, compressing vessels and reducing bleeding - Administer as prescribed; monitor effect on fundal firmness and lochia 6. **Position for Optimal Circulation:** - Keep the mother flat or in a slight Trendelenburg position (head of bed lowered ~10 degrees) if hemorrhagic shock is suspected - Slightly elevate the lower extremities to promote venous return to the heart - This position is temporary; avoid prolonged Trendelenburg as it increases intracranial pressure 7. **Keep the Mother Warm:** - Cover with warm blankets; use warmed IV fluids - Hypothermia worsens coagulopathy (the "lethal triad" of trauma is hypothermia, acidosis, and coagulopathy) 8. **Measure and Document Intake and Output:** - Insert a urinary catheter to monitor urine output (target >0.5 mL/kg/hr, roughly 30–40 mL/hr for an adult) - Count and weigh pads; record lochia characteristics and volume - Document vital signs every 5–15 minutes during active hemorrhage - Calculate estimated blood loss and cumulative fluid balance 9. **Administer Blood Products if Ordered:** - Type O negative packed red blood cells (O- is the universal donor) may be used if type and crossmatch is not complete - Follow facility protocol for massive transfusion - Monitor for transfusion reactions (fever, chills, rash, dyspnea, hemoglobinuria) 10. **Prepare for Possible Transfer or Advanced Interventions:** - In resource-limited settings, early transfer to a higher-level facility is crucial - Advanced interventions (if bleeding does not stop with initial measures) include uterine balloon tamponade, angiographic embolization of the uterine artery, or hysterectomy - Keep the mother and family informed; support the family during this crisis **Specific Assessment Red Flag:** If a mother who received oxytocin during labor develops PPH, suspect uterine rupture (especially if prior cesarean) rather than simple atony. Uterine rupture presents with severe, persistent pain, shock out of proportion to visible bleeding, and fetal parts palpable in the abdomen.

Uterotonics (also called oxytocics) stimulate sustained uterine muscle contraction, compressing myometrial vessels and controlling bleeding. The choice of agent depends on the clinical scenario, contraindications, and available resources. Understanding the contraindications is high-yield for the NLE. **Oxytocin (Pitocin):** **Mechanism:** Stimulates rhythmic uterine contraction through receptor binding. Causes a sustained contraction with rhythmic increases in tone, ideal for controlling postpartum bleeding. **Dosing:** - Intravenous infusion: 10–40 units diluted in 1 liter of crystalloid fluid, infused at a rate titrated to uterine response (typically 10–20 mL/min initially, increased as needed). Do NOT give concentrated oxytocin IV push; this causes sudden hypertension and coronary vasospasm. - Intramuscular injection: 10 units IM as a single dose (faster onset than IV infusion but slower than IV bolus) - Intranasal spray: 10 units (used in some settings for third-stage labor but not for established PPH) **Onset and Duration:** IV infusion onset is immediate; IM onset is 3–5 minutes. Effects last 15–60 minutes depending on route. **Advantages:** - First-line agent; no absolute contraindications (unlike ergot derivatives and prostaglandins) - Rapid onset - Short half-life (side effects reverse quickly if stopped) - Safe in hypertension (unlike methylergonovine) - Safe in asthma (unlike carboprost) **Side Effects:** Antidiuretic effect (fluid retention, hyponatremia if excessive fluid administered), transient hypertension (especially with bolus), headache, nausea, reflex bradycardia, and rarely cardiac arrhythmias or myocardial ischemia. **Monitoring:** Assess blood pressure, uterine tone, and lochia frequently. Titrate infusion to avoid hyperstimulation (tetanic contractions, abdominal pain, uterine rupture). **Methylergonovine (Methergine, Methylergometrine):** **Mechanism:** Ergot alkaloid that causes sustained, tetanic uterine contraction (not rhythmic). More potent than oxytocin but less selective; causes vasoconstriction systemically. **Dosing:** - Intramuscular: 0.2 mg (200 mcg) IM. May repeat every 2–4 hours if needed (maximum 5 doses). - Intravenous: 0.2 mg IV over 1–2 minutes only if IV access is already established and the situation is emergent. IV administration risks sudden hypertensive crisis; IM is preferred. - Oral: 0.2 mg orally three times daily for up to 7 days (used for late PPH or subinvolution after the acute phase) **Onset and Duration:** IM onset is 6–8 minutes; IV onset is 1–2 minutes. Effects persist 3–6 hours or longer. **Advantages:** - Potent; sustained contraction (tetanic) is effective for severe bleeding - Longer duration than oxytocin - Oral form allows outpatient management of late PPH **CRITICAL Contraindications:** - **Hypertension or preeclampsia/eclampsia.** Methylergonovine causes potent vasoconstriction and may precipitate severe hypertension, stroke, myocardial infarction, or eclamptic seizure. **Check BP before each dose.** If BP ≥160/110, do NOT administer. - **Coronary artery disease** (risk of vasospasm and MI) - **Peripheral vascular disease** - **Uncontrolled hypertension** **Side Effects:** Hypertension (the major concern), vasoconstriction, headache, dizziness, nausea, vomiting, chest pain, palpitations, and (rarely) myocardial infarction or stroke. **NLE High-Yield Point:** "Before giving methylergonovine, check the blood pressure. If elevated (especially ≥160/110 or if the mother is preeclamptic), do NOT give it." **Carboprost (Hemabate, 15-Methyl PGF2-Alpha):** **Mechanism:** Synthetic prostaglandin F analog that stimulates sustained myometrial contraction and also causes systemic smooth muscle contraction (bronchial and vascular). **Dosing:** - Intramuscular or intra-amniotic: 250 mcg (0.25 mg) IM initially; may repeat every 15–90 minutes as needed (maximum 8 doses or 2 mg total). Usual maximum effect occurs within 1–2 hours. **Onset and Duration:** IM onset is within a few minutes; peak effect in 30–60 minutes; duration several hours. **Advantages:** - Potent; effective for severe atony unresponsive to oxytocin - Can be used when contraindications to oxytocin or methylergonovine exist (though see contraindications below) - Works through a different mechanism than oxytocin and ergot, useful as a "rescue" agent **CRITICAL Contraindications:** - **Asthma or chronic obstructive pulmonary disease.** Prostaglandins cause bronchial smooth muscle contraction and severe bronchospasm. This is an absolute contraindication; do NOT use in any woman with reactive airway disease. - **Severe hepatic or renal disease** (impaired metabolism/clearance) - **Cardiovascular instability** **Side Effects:** Fever (very common, 50–80% of women), shivering, chills, diarrhea, nausea, vomiting, tachycardia, hypertension, chest pain (bronchospasm if not contraindicated), and flushing. Fever is expected and not a sign of infection; reassure the mother and administer antipyretics. **NLE High-Yield Point:** "Carboprost is contraindicated in asthma because it causes bronchospasm." **Misoprostol (Cytotec, a Prostaglandin E1 Analog):** **Mechanism:** Synthetic prostaglandin E1 that stimulates uterine contraction and is also cytoprotective to gastric mucosa (its original indication). **Dosing:** - Rectal (rectally inserted): 600–1,000 mcg (most common route postpartum) - Oral: 600–1,000 mcg orally - Sublingual: 400–600 mcg under the tongue **Onset and Duration:** Onset within 10–15 minutes (rectal route); peak effect 30–60 minutes; duration 3–4 hours. **Advantages:** - Inexpensive and thermostable (does not require refrigeration), making it ideal for low-resource settings such as Philippine Barangay Health Stations and Rural Health Units without reliable electricity or refrigeration - Oral, rectal, or sublingual administration; no injection needed - Effective for prevention and treatment of PPH - Side effect (fever) is expected and self-limiting - Often used as first-line in resource-limited settings **Side Effects:** Fever (very common), shivering, diarrhea, nausea, vomiting, and abdominal cramping. These side effects are dose-dependent and usually transient. **Monitoring:** Assess for excessive fever (>39°C); administer antipyretics if needed. Misoprostol is not contraindicated in asthma or hypertension, making it safer for women with these conditions. **Combination Approach in Clinical Practice:** Often, uterotonics are used in combination: 1. Start with oxytocin (first-line, no contraindications in most women) — IV infusion at 10–20 mL/min 2. If inadequate response after 5–10 minutes, add methylergonovine 0.2 mg IM (if BP is normal) OR misoprostol 600–1,000 mcg rectally 3. If still inadequate, add carboprost 250 mcg IM (if not contraindicated by asthma) 4. If massive hemorrhage persists, prepare for uterine balloon tamponade, angiographic embolization, or surgical intervention **Assessment Before Administering Uterotonics:** - Blood pressure (critical for methylergonovine; check before each dose) - Respiratory history (asthma/COPD rules out carboprost) - Current medications and allergies - Uterine tone and fundal height - Lochia characteristics (quantity, color, odor) - Vital signs - Patient response to previous dose (if already given) **Documentation in the Nursing Record (RA 9173 Requirement):** As per RA 9173 professional standards, carefully document: - Time of uterotonic administration - Route (IV, IM, rectal, oral) and dose - Uterine response (fundal firmness, height, contraction pattern) - Lochia volume and character - Vital signs before and after administration - Any adverse effects - Mother's tolerance and subjective response

Puerperal infection, also called postpartum infection, is a potentially life-threatening complication that affects approximately 1–3% of postpartum women. Understanding its definition, risk factors, clinical presentation, and management is essential for the NLE and for preventing maternal morbidity and mortality in Philippine healthcare settings. **Definition:** Puerperal infection is defined as a temperature of **38°C (100.4°F) or higher on any two of the first 10 postpartum days** (excluding the first 24 hours). The definition intentionally excludes the first 24 hours to avoid false positives from labor-related fever. This definition is derived from a classic study and remains the standard for clinical recognition. Alternatively, some sources define it as fever ≥38.5°C on a single occasion after the first postpartum day, indicating a more acute/severe infection. **Pathophysiology:** The postpartum uterus is an ideal culture medium: the placental site is a large, open wound with raw surface area, lochia (dead tissue and blood) provides nutrients, and the cervix remains partially open until ~day 10, allowing ascending bacterial colonization. The postpartum immunosuppression (relative to pregnancy demands) combined with tissue trauma creates the "perfect storm" for infection. **Types of Puerperal Infection:** 1. **Endometritis (Infection of the Uterine Lining) — Most Common (60–70% of cases):** Inflammation and infection of the endometrium and superficial myometrium. Can progress to myometritis (deeper myometrial involvement) or parametritis (infection spreading to the broad ligament). 2. **Wound Infection:** - Episiotomy or perineal laceration infection (rare, ~1–3% of vaginal births) - Cesarean section wound infection (more common after cesarean, ~5–15% depending on risk factors) - Presents as localized warmth, erythema, edema, purulent drainage, dehiscence (opening), or abscess 3. **Urinary Tract Infection (UTI) and Pyelonephritis:** - Catheterization, prolonged catheterization, incomplete bladder emptying, and urinary stasis increase risk - UTI alone may not produce fever; pyelonephritis does - Presents with dysuria, urgency, frequency; fever; flank pain (pyelonephritis) 4. **Mastitis:** - Inflammation/infection of breast tissue in lactating mothers (covered separately below) 5. **Septic Thrombophlebitis:** - Infection of a blood clot (rare but serious); often associated with severe endometritis or cesarean delivery - Presents with persistent fever despite antibiotics, unilateral leg swelling, and pain **Risk Factors for Puerperal Infection:** - **Cesarean delivery** — the single most significant risk factor (5–15× greater risk than vaginal delivery) - **Prolonged rupture of membranes (PROM):** >12–18 hours before delivery increases ascending infection risk; risk increases significantly >24 hours - **Prolonged labor:** prolonged labor increases maternal exhaustion, operative intervention risk, and bacterial exposure - **Multiple vaginal exams during labor:** each exam introduces bacteria into the genital tract - **Manual removal of placenta:** reduces uterine surface trauma but introduces manipulation/infection risk - **Retained placental fragments:** prevents full involution and provides material for bacterial overgrowth - **Intra-amniotic infection (chorioamnionitis):** infection present at delivery increases postpartum infection risk - **Hemorrhage:** blood loss worsens immune response and tissue perfusion - **Maternal factors:** obesity (increased surgical site complications), diabetes (impaired immunity), anemia, immunosuppression, poor nutritional status - **Socioeconomic factors:** limited access to prenatal care, poor hygiene, delayed postpartum care - **Operative delivery:** forceps or vacuum extraction (though risk is lower than with cesarean) **Clinical Presentation of Endometritis (Most Common Form):** **Cardinal Signs:** - **Fever** (≥38°C on postpartum day 2–10, or present earlier if severe infection) - **Uterine tenderness:** fundus is tender to palpation; may be boggy or remain firm - **Foul-smelling or profuse lochia:** The classic sign is lochia with a foul, putrid, or "rotten meat" odor. Lochia may also be excessive in quantity or return to bright red after appropriate progression to serosa/alba (failure of normal progression indicates retained products and infection). **Associated Signs and Symptoms:** - Chills and rigors (body shaking from high fever) - **Tachycardia** (heart rate often 110–130 bpm) - Tachypnea (respiratory rate >20 breaths/min) - Headache and malaise (general body aches) - Loss of appetite - Weakness and fatigue - Abdominal pain or cramping (distinct from normal postpartum discomfort) **Assessment Findings:** - Elevated white blood cell count (WBC typically 15,000–30,000 or higher; normal postpartum WBC is elevated ~10,000–15,000, so infection elevates it further) - C-reactive protein (CRP) elevated - Blood cultures may grow causative organisms (gram-positive cocci like Group B Streptococcus, Staphylococcus aureus; gram-negative rods like E. coli; or anaerobes) - Ultrasound may show thickened endometrium, fluid collection, or gas in the uterus - In severe cases: signs of sepsis (hypotension, tachycardia, oliguria, altered mental status, DIC-like picture) **Causative Organisms:** Postpartum infection is typically polymicrobial (multiple organisms); common agents include: - **Gram-positive:** Streptococcus agalactiae (Group B Strep), Streptococcus pyogenes (Group A Strep, rare but can cause rapid/fulminant infection), Staphylococcus aureus - **Gram-negative:** Escherichia coli (E. coli), Klebsiella, Proteus - **Anaerobes:** Bacteroides, Prevotella, Clostridium perfringens (rare, causes gas gangrene/emphysema) - **Atypical:** Mycoplasma hominis, Ureaplasma urealyticum **Nursing Diagnosis (NANDA) and Priority Assessment:** Using NANDA-I taxonomy and Maslow's hierarchy: - **Risk for Infection/Infection** (secondary to tissue trauma, open placental site, ascending bacteria) — High priority on Maslow's physiological and safety needs levels - **Risk for Sepsis/Septic Shock** (if infection progresses) — Life-threatening - **Hyperthermia** (related to inflammatory response to infection) - **Ineffective Tissue Perfusion** (if sepsis develops) - **Deficient Knowledge** (regarding infection prevention and signs to report) — Important for self-care and early detection **Priority Nursing Management:** **1. Assessment and Monitoring:** - Measure temperature every 2–4 hours; maintain a fever chart - Assess fundal firmness and height; assess for tenderness by gentle palpation - Inspect lochia closely: color, consistency, odor, and amount - Monitor vital signs frequently (every 2–4 hours initially; every 1–2 hours if signs of sepsis) - Monitor for signs of sepsis: confusion, altered mental status, persistent hypotension, oliguria, cool/clammy extremities, petechial rash - Assess abdominal pain: location, onset, severity, character (crampy, sharp, dull), radiation, aggravating/alleviating factors - Assess for lower abdominal or flank tenderness (suggesting parametritis or pyelonephritis) **2. Laboratory Work (Obtain Before Starting Antibiotics, if Possible):** - Blood cultures (aerobic and anaerobic bottles) — critical for identifying organisms and guiding antibiotics; obtained before antibiotics started - Complete blood count (CBC) with differential: elevated WBC suggests infection - Metabolic panel: assess kidney function (especially important if gentamicin is used) - Coagulation studies if sepsis suspected - Urinalysis and urine culture if UTI suspected - Endometrial culture (less commonly done; culture via sterile catheter or aspiration of lochia) - Blood glucose (if diabetic, infection worsens hyperglycemia) **3. Pharmacological Management — Antibiotic Therapy:** **Antibiotic Selection and Timing:** Antibiotics are initiated **as soon as infection is suspected (fever ≥38°C + clinical signs)**; do not delay for culture results. Broad-spectrum coverage is needed to cover gram-positive, gram-negative, and anaerobic organisms. **First-Line Antibiotic Regimens (IV):** - **Clindamycin 600–900 mg IV every 6–8 hours PLUS Gentamicin 5 mg/kg IV once daily (or 1.5 mg/kg every 8 hours):** - Clindamycin: covers gram-positive (including S. aureus, Group B Strep) and anaerobes - Gentamicin: covers gram-negative organisms - Combination achieves broad spectrum coverage - Gentamicin is an aminoglycoside; monitor renal function and drug levels (trough level) to avoid nephrotoxicity - **Ceftriaxone 1–2 g IV every 12 hours PLUS Clindamycin 600–900 mg IV every 6–8 hours** (or plus Metronidazole 500 mg IV every 8 hours for anaerobic coverage): - Ceftriaxone: broad-spectrum cephalosporin, covers gram-positive and gram-negative - Excellent for perioperative prophylaxis and treatment - Total duration of IV therapy: typically 24–48 hours after fever resolves and clinical improvement; then transition to oral antibiotics (e.g., amoxicillin-clavulanate 500 mg po three times daily) to complete 10–14 days total - **Ampicillin 1–2 g IV every 6 hours PLUS Gentamicin 5 mg/kg IV once daily PLUS Clindamycin 600–900 mg IV every 6–8 hours** (triple therapy, less commonly used now but effective): - Covers gram-positive, gram-negative, and anaerobes - Ampicillin covers Group B Strep excellently **In Philippine Context (RA 9173 and Availability):** Choice depends on: - Local antibiotic resistance patterns and institutional protocols - Drug availability (some rural facilities may lack certain antibiotics) - Cost (gentamicin + clindamycin may be more affordable than newer cephalosporins) - Patient factors (renal function for aminoglycosides) The obstetrician or perinatologist (in hospital settings) determines the specific regimen; the nurse ensures timely administration, monitoring, and documentation. **Special Considerations:** - If **MRSA (methicillin-resistant Staphylococcus aureus)** is suspected (history of MRSA colonization, healthcare-associated infection risk): use **vancomycin 15–20 mg/kg IV every 8–12 hours** or **linezolid 600 mg IV every 12 hours** - If **Clostridium difficile** is suspected (after prolonged antibiotic use): **metronidazole 500 mg IV every 6–8 hours** or **oral vancomycin** (not absorbed systemically but high local concentration in the colon) - **Lactating mothers:** Most antibiotics are safe during breastfeeding (gentamicin, cephalosporins, clindamycin are excreted in small amounts in milk and are not harmful to infants). Reassure the mother that she can continue breastfeeding during antibiotic therapy. **4. Supportive Care and Nursing Interventions:** - **Rest and Activity:** Encourage rest; position in **semi-Fowler (head of bed elevated 30–45 degrees)** to promote gravity-assisted lochia drainage down the vaginal canal, reducing retrograde flow into the fallopian tubes and peritoneal cavity - **Hydration:** IV fluids (Normal Saline or Lactated Ringer's at 75–100 mL/hr) to maintain hydration and facilitate antibiotic distribution; monitor intake/output; goal is urine output >0.5 mL/kg/hr (~30–40 mL/hr) - **Antipyretics:** Acetaminophen 500–1,000 mg orally/IV every 4–6 hours or ibuprofen 400–600 mg orally every 6 hours to reduce fever and discomfort. Monitor temperature response; reassess vital signs 30–60 minutes after antipyretic administration - **Perineal Care and Hygiene:** - Teach and assist with perineal hygiene: use warm water and mild soap; wash from front to back (urethra to anus) to avoid contaminating the vagina with rectal flora - Change pads frequently (every 2–4 hours or when saturated) to reduce bacterial overgrowth on the perineum - Perform sitz baths (sit in warm water, ~43°C) for 10–15 minutes, 3–4 times daily: promotes comfort, local circulation, and drainage - Avoid douching (increases infection risk; disrupts normal flora) - Teach handwashing before and after perineal care - **Lochia Monitoring and Management:** - Inspect lochia after each perineal wash; note color, consistency, odor, and amount - Document changes; a return to normal progression (from rubra → serosa → alba) after antibiotic initiation is reassuring - Ambulation (when allowed and tolerated): promotes uterine drainage and circulation; mobilize as tolerated - Avoid anything that might introduce infection: tampons (use pads), bubble baths, intercourse, inserting anything into the vagina - **Pain Management:** - Assess pain location and character; distinguish between normal postpartum cramping (dysphoria from contractions) and infection-related pain (tenderness, peritoneal signs) - Analgesics: acetaminophen 500–1,000 mg orally every 4–6 hours; ibuprofen 400–600 mg orally every 6 hours (NSAIDs reduce both pain and fever); narcotic analgesics (e.g., codeine sulfate 30–60 mg orally every 4–6 hours) if needed, but avoid excess as they slow GI motility - Warm compress to the lower abdomen (not directly over the uterus) may provide comfort - **Monitoring for Complications:** - Watch for signs of sepsis and septic shock: continued fever despite antibiotics, worsening tachycardia, hypotension, oliguria, altered mental status, skin pallor/mottling, cold extremities - Watch for signs of septic thrombophlebitis: persistent fever, leg swelling and pain, positive Homan's sign (unreliable but noted) - Watch for signs of abdominal peritonitis: rebound tenderness, guarding, rigid abdomen, severe pain — requires urgent surgical evaluation - Monitor antibiotic side effects: aminoglycosides (gentamicin) can cause ototoxicity and nephrotoxicity; monitor renal function and signs of hearing loss; clindamycin can cause diarrhea (watch for C. difficile); cephalosporins risk allergic reactions **5. Patient Education and Discharge Planning:** - Teach the mother to recognize signs of infection and when to report them: fever >38°C, foul-smelling lochia, vaginal bleeding exceeding pad saturation (>1 pad per hour), severe abdominal pain, chills, malaise, or symptoms worsening despite antibiotics - Complete the full course of prescribed oral antibiotics at home, even if feeling better - Maintain good hygiene: perineal care, handwashing, frequent pad changes - Rest adequately; gradually increase activity - Maintain good nutrition and hydration to support healing and immune function - Return for follow-up postpartum visit (usually 2–4 weeks postpartum) to assess healing and confirm infection resolution - If signs worsen or new symptoms develop, return immediately to the healthcare facility **Prognosis and Outcomes:** With appropriate antibiotic therapy and supportive care, the majority of endometritis cases resolve within 48–72 hours (fever resolves, clinical symptoms improve). Delayed response to antibiotics should prompt investigation for complications (abscess formation, septic thrombophlebitis, retained placental fragments). In the pre-antibiotic era, puerperal sepsis was a leading cause of maternal death; today, with modern antibiotics and supportive care, maternal mortality from infection is rare in well-resourced settings but remains a concern in resource-limited areas.

Mastitis is inflammation or infection of the breast tissue, typically occurring in lactating mothers during the early postpartum period. While often painful and distressing, mastitis is manageable with appropriate nursing intervention and antibiotic therapy, and breastfeeding should be continued (despite discomfort) to prevent complications like breast abscess. **Epidemiology:** Mastitis occurs in approximately 1–3% of breastfeeding mothers, with peak incidence **2–4 weeks postpartum**, though it can occur anytime during lactation. The condition is rare in non-lactating women and even rarer in bottle-feeding mothers. **Pathophysiology and Types:** **1. Non-Infectious Mastitis (Milk Stasis/Engorgement Mastitis):** Inflammation of breast tissue without bacterial infection, caused by milk accumulation and stasis in the ducts. This is the more common form and may precede or occur without bacterial infection. **Causes of milk stasis:** - **Incomplete emptying:** infrequent feedings, skipped feedings, using only one breast - **Poor latch or positioning:** infant does not effectively remove milk; common in first-time breastfeeding mothers - **Engorgement:** breast swelling from milk accumulation in the early postpartum period or when feedings are missed - **Blocked milk duct:** a duct becomes obstructed, usually by a thickened milk plug, fibrous tissue narrowing, or pressure from a tight bra or sleeping position - **Oversupply of milk:** excessive milk production relative to infant demand **Clinical presentation of milk stasis:** localized breast swelling, warmth, redness (erythema), and tenderness, usually WITHOUT fever or systemic symptoms. The area may be hard, painful to touch, and produce no pus. Symptoms resolve with improved milk drainage (frequent feedings, massage, warm compresses before feeds). **2. Infectious Mastitis (Bacterial Infection):** Bacterial superinfection of milk-stasis-associated inflammation, or primary bacterial infection through a cracked or fissured nipple. The breach in skin integrity allows bacteria from the mother's skin or infant's mouth to enter the breast tissue. **Causative organisms:** - **Staphylococcus aureus** — the most common cause (~50% of cases), including MRSA in healthcare-associated infections - **Streptococcus agalactiae (Group B Strep)** — less common but can cause severe infection - **Corynebacterium species** and other skin flora - Rarely, gram-negative organisms if severe infection/abscess forms **Pathophysiology:** Bacteria enter through the cracked nipple, migrate to the breast parenchyma (functional tissue), and trigger an inflammatory response. Stasis of milk in ducts provides a culture medium for bacterial growth. Unlike non-infectious mastitis, bacterial infection causes systemic inflammation (fever, chills, body aches) due to bacterial toxins and immune response. **Clinical Presentation of Infectious Mastitis:** **Cardinal Features:** - **Unilateral breast involvement** (one breast affected, not bilateral; bilateral mastitis is rare and suggests more severe systemic infection) - **Localized area of inflammation:** wedge-shaped or quadrant-specific area of the breast (usually upper outer quadrant, as this is the most common site of milk duct obstruction). The affected area is: - **Erythematous (red)** — bright red or red-purple - **Warm to touch** — noticeably warmer than the contralateral breast - **Hard/induration** — firm, swollen tissue; palpable lump or nodule - **Tender** — painful to touch; may be exquisitely tender - **Systemic symptoms** (the key differentiator from non-infectious engorgement): - **Fever:** ≥38.5°C; often with chills and rigors - **Malaise:** general body aches, flu-like symptoms - **Fatigue and weakness** - **Headache** and general ill feeling **Timeline:** Symptoms typically develop **acutely over 24–48 hours** — the mother may wake up feeling ill with fever and discover breast pain/redness. **Risk Factors:** - **Cracked or fissured nipples:** the primary entry point for bacteria; common in early postpartum period due to nursing technique learning curve - **Milk stasis/engorgement:** provides the inflammatory milieu and stagnant milk culture medium - **Infrequent feedings or missed feedings:** interrupted nursing rhythm causes stasis - **Oversupply of milk:** especially in the first 2–4 weeks - **Poor latch:** infant does not attach correctly; ineffective milk removal and potential nipple trauma - **Tight bras or pressure on the breast:** sleeping on one side, tight bra straps, or pressure from carrying the infant restricts milk flow - **Breast engorgement:** swollen, tense breast tissue compromises circulation and milk drainage - **Maternal fatigue or stress:** poor immune function and neglect of self-care (including feeding frequency) - **Prior episodes of mastitis:** prior infection increases recurrence risk **Differentiation: Mastitis vs. Breast Abscess:** A **breast abscess** develops if mastitis is inadequately treated or if bacteria continue to replicate and liquefy tissue. Signs include: - Persistent fever despite antibiotics (after 48–72 hours) - Fluctuance on palpation (soft, fluid-filled collection) - Possible spontaneous drainage of pus - Requires imaging (ultrasound) and possible aspiration/drainage Abscess is a complication of mastitis that can be prevented with early, aggressive treatment. **Nursing Diagnosis (NANDA) and Priority Assessment:** Using NANDA-I and Maslow: - **Acute Pain** (related to inflammation/infection and engorgement) — affects activity and self-care - **Infection/Risk for Infection** (related to cracked nipple; risk for progression to abscess) — physiological safety need - **Ineffective Breastfeeding** (related to pain, fear of worsening infection, or incorrect latch) — affects infant nutrition and maternal-infant bonding - **Anxiety** (related to pain, concern for infant safety, fear of having to stop breastfeeding) — psychosocial need - **Deficient Knowledge** (regarding mastitis prevention and treatment; importance of continuing breastfeeding) — education priority **Priority Nursing Management for Infectious Mastitis:** **1. Accurate Assessment and Diagnosis:** - **Obtain a detailed history:** - Onset and duration of symptoms - Breastfeeding pattern: frequency, duration per breast, which breast(s) affected - Nursing technique: latch quality, positioning - Nipple condition: cracked, fissured, bleeding - Recent engorgement or missed feedings - Systemic symptoms: fever, chills, body aches - Prior episodes of mastitis or other infections - Stress level, sleep, nutrition (factors affecting immunity) - **Physical examination of the breast:** - Bilateral breast examination: compare affected side to unaffected side - Palpate for area(s) of induration, warmth, erythema; note size and location - Assess nipple: cracks, fissures, bleeding, discharge (clear, purulent, bloody) - Check for lymphadenopathy (axillary or supraclavicular nodes; suggest infection) - Perform gentle massage of the affected area to assess for fluctuance (abscess) - Assess pain level and impact on function - **Laboratory/Imaging (if indicated):** - **Breast milk culture:** expressing milk from the affected breast into a sterile container for culture; identifies the causative organism. This is especially useful if initial antibiotic therapy fails (suggesting resistant organism) or if abscess is suspected. - **Ultrasound:** if abscess is suspected (persistent fever after 48–72 hours of antibiotics, fluctuance on palpation); ultrasound shows the extent of inflammation and presence of fluid collection - **Blood cultures:** rarely obtained unless severe systemic infection (sepsis) is suspected - **Temperature and vital signs:** obtain baseline; monitor every 4–6 hours, especially in the first 48 hours **2. Pharmacological Management:** **Antibiotic Therapy:** Antibiotics targeting Staphylococcus aureus (and covering other gram-positive bacteria) are initiated immediately; do not wait for culture results. **First-Line Oral Antibiotics (if not severe/septic):** - **Dicloxacillin 500 mg orally four times daily for 10–14 days** — beta-lactamase–resistant penicillin, excellent coverage for non-MRSA Staph aureus. However, dicloxacillin is becoming less available; check local availability. - **Cephalexin 500 mg orally four times daily for 10–14 days** — first-generation cephalosporin; covers Staph aureus and other gram-positive organisms; good for breastfeeding - **Amoxicillin-clavulanate 500 mg orally three times daily for 10–14 days** — amoxicillin is a beta-lactam; clavulanate inhibits beta-lactamase, protecting amoxicillin from enzymatic breakdown; effective against penicillinase-producing Staph aureus **If MRSA is Suspected (healthcare-associated, prior MRSA colonization, or severe infection):** - **Clindamycin 300–450 mg orally every 6–8 hours for 10–14 days** — covers MRSA and non-MRSA Staph aureus; enters breast tissue and milk well - **Trimethoprim-sulfamethoxazole (TMP-SMX) DS one tablet (160 mg TMP / 800 mg SMX) orally twice daily for 10–14 days** — covers MRSA; generally safe in breastfeeding but use caution with infants <2 months old (risk of kernicterus, though minimal) **If Severe/Septic (Rare):** - **IV antibiotics** (e.g., IV cephalexin 1–2 g every 6–8 hours or IV clindamycin 600–900 mg every 6–8 hours) — for signs of sepsis, persistent fever, inability to tolerate oral intake, or if abscess suspected **Safety in Breastfeeding:** **All of the antibiotics above are safe during breastfeeding.** The amounts excreted in breast milk are minimal and not harmful to the infant. Reassure the mother that continuing to breastfeed is safe, beneficial, and actually therapeutic. **Duration of Antibiotic Therapy:** Continue antibiotics for the **full 10–14 days**, even if symptoms resolve after a few days. Incomplete antibiotic courses risk recurrence or progression to abscess. Encourage adherence. **3. Supportive Care and Comfort Measures:** **Thermal Therapy:** - **Warm compresses before feeding:** Apply a warm compress (warm water-soaked cloth or heating pad) to the affected breast for 10–15 minutes BEFORE feeding or expressing. Warmth: - Promotes vasodilation and improves circulation - Softens the breast tissue and milk ducts - Facilitates milk letdown (oxytocin reflex) - Reduces pain and stiffness - **Cold compresses after feeding:** Apply cold (ice pack or cold gel pack) for 10–15 minutes AFTER feeding/expressing. Cold: - Reduces edema and inflammation - Decreases pain and soreness - Slows local blood flow **Milk Removal (THE MOST CRITICAL INTERVENTION):** **Continue breastfeeding or expressing milk; do NOT stop.** This is a frequent misconception by mothers fearing harm to the infant. Emptying the breast is the single most important therapeutic measure. **Why continue breastfeeding:** - Frequent, effective milk removal is the treatment for mastitis (both milk stasis and bacterial infection) - The affected breast produces antibodies and white blood cells that fight the infection; milk from the infected breast is safe for the infant to consume - Stopping breastfeeding causes milk accumulation, worsening stasis, and perpetuating the infection (or leading to abscess) - The infant is unlikely to contract the infection; the milk has protective immune factors **Optimal feeding strategy during mastitis:** - **Start each feeding on the AFFECTED breast** (when infant's suck is strongest) to ensure vigorous milk removal from that side - **Use proper positioning and latch** to optimize milk drainage - **Feed frequently:** 8–12 times per day or more; empty the breast with each feeding - **Alternate feeding positions:** upright, side-lying, and "football hold" (different positions drain different areas of the breast) - **Between feedings, express milk manually or with a pump** if the breast is still full or uncomfortable; manual expression of a small amount can relieve pressure and discomfort without overstimulating production - **Avoid prolonged engorgement between feedings** — this perpetuates stasis **Breast Massage:** - During warm compress application, **gently massage the affected area** in a circular motion from the affected area toward the nipple. Massage promotes circulation and may help dislodge milk plugs - Firm, aggressive massage is not recommended as it increases pain and inflammation - Gentle massage combined with feeding aids drainage **Pain Management:** - **Analgesics:** Acetaminophen 500–1,000 mg orally every 4–6 hours or ibuprofen 400–600 mg orally every 6 hours. NSAIDs (like ibuprofen) are preferred as they also reduce inflammation. Both are safe during breastfeeding. - **Timing:** Take analgesic 15–30 minutes before planned feeding/expressing to allow peak effect during milk removal - **Breast support:** Wear a well-fitting, supportive bra (not too tight) to reduce breast movement and provide comfort. Some mothers prefer a bra that can be quickly unsnapped for frequent feeds. - **Rest and elevation:** Elevate the affected breast when sitting or lying to reduce swelling (though not at the expense of frequent feeding) **Nipple Care:** - **If cracked or fissured:** assess healing; use proper latch technique to prevent further trauma - **Nipple pads or shells:** if nipple damage is significant, express milk manually or with a pump for 1–2 feedings to allow nipple rest, then resume direct breastfeeding - **Lanolin or purified lanolin:** apply after feeding to soothe and protect (though evidence for benefit is limited, it is harmless) - **Correct latch:** This is crucial. If latch is the underlying cause, poor latch will perpetuate mastitis with each feed. Consider lactation consultant evaluation **General Supportive Care:** - **Rest:** Encourage adequate sleep (often difficult with a newborn, but napping when the infant sleeps helps) - **Hydration:** Drink 2–3 liters of fluids daily (water, herbal tea, juice); hydration supports milk production and systemic health - **Nutrition:** Eat regular, balanced meals; caloric demands of lactation are high (adds ~500 kcal/day above maintenance) - **Stress reduction:** Stress and fatigue impair immune function and milk letdown; relaxation techniques (deep breathing, meditation) and support from family/partner help - **Avoid tight clothing or pressure:** Sleep on alternate sides; avoid tight bras, breast pressure from carrying infant; these limit milk flow **4. Monitoring and Assessment of Response:** **Expected Timeline:** - With appropriate antibiotic therapy and frequent milk drainage, **fever typically resolves within 24–48 hours** - **Breast tenderness, erythema, and induration improve over 3–7 days** - **Complete resolution usually occurs within 10–14 days** (duration of antibiotic therapy) **Assess at each feeding and daily:** - Temperature: should normalize within 24–48 hours; persistent fever after 48 hours suggests inadequate antibiotic coverage, abscess formation, or non-compliance with feeding/drainage - Breast tenderness: should improve with each day of therapy and continued milk drainage - Erythema and warmth: should fade as inflammation resolves - Induration (hardness): may take several days to soften; should progress toward resolution - Lochia: observe that lochia is normal (not infected); some mothers mistakenly attribute systemic symptoms to postpartum infection when it is actually mastitis - Nipple condition: assess for further trauma; erythema from friction should heal **Signs of Inadequate Response or Complication (Abscess):** - **Persistent fever after 48–72 hours of antibiotics** (despite appropriate feeding/drainage) - **Worsening or localized fluctuance** (soft, fluid-filled mass) - **Increasing pain and erythema** (not improving after 48–72 hours) - **Systemic deterioration:** increasing malaise, chills, tachycardia - Suspect **breast abscess** if above signs present **Management if abscess suspected:** - Ultrasound to confirm and determine size - If small (<1 cm): continue antibiotics and milk drainage; may resolve without intervention - If larger or persistent: needle aspiration (FNA) or surgical drainage may be needed - Even with drainage, continue breastfeeding from the affected side; drainage does not contraindicate lactation **5. Patient Education and Prevention:** **Prevention of Mastitis (Primary Prevention — Teach Early Postpartum):** 1. **Proper latch and positioning:** - Baby's mouth covers the entire areola, not just the nipple - Baby's chin and nose touch the breast - No pain during feeding (mild discomfort in first week is normal; sharp pain suggests poor latch) - Audible swallowing indicates effective milk transfer - Consider lactation consultant if uncertain; skilled guidance prevents latch problems and mastitis 2. **Frequent feeding:** Feed 8–12 times per day (or more); do not try to "space out" feedings (common misconception from older advice). Frequent, effective feeding prevents stasis. 3. **Alternate breasts and starting position:** Start each feed alternating between breasts; this ensures both breasts are emptied regularly. Vary feeding position to drain different areas. 4. **Empty the breast:** Ensure infant removes milk effectively; if doubts, express after feeding to assess residual milk. 5. **Avoid tight bras and pressure:** Wear a comfortable, well-fitting (not tight) bra; avoid sleeping on one side persistently (rotate sleep positions); do not carry infant with pressure on one breast. 6. **Manage engorgement:** In the first week postpartum (engorgement phase), frequent feeding is the best prevention. Some mothers find cool compress after feeding (to reduce swelling) helpful. Avoid suppressing lactation unless necessary. 7. **Nipple care:** Wash breasts with water (not soap, which dries skin); avoid cracked/fissured nipples by ensuring proper latch and position. If nipples crack, treat early (lanolin, hydrogel pads, brief feeding breaks if severe). 8. **Rest and stress management:** Fatigue impairs immunity and milk letdown. Adequate rest, stress reduction, and support from partner/family reduce mastitis risk. 9. **Nutritious diet and hydration:** Support lactation and immune function. **Secondary Prevention (Teach if Mastitis Develops):** - Continue breastfeeding (as above) - Seek early treatment: mastitis is not an emergency but should be treated promptly to prevent abscess - Strict antibiotic adherence: complete the full course even if feeling better **Discharge Planning and Follow-up:** - Review antibiotic instructions: complete the full 10–14 days - Provide written instructions on breastfeeding technique, warm/cold compress use, and pain management - If lactation consultation was not offered, recommend it, especially if latch issues contributed to mastitis - Schedule follow-up contact (by phone or in-person) within 48 hours to assess response to antibiotics - Provide contact information for lactation support and healthcare access if symptoms worsen - Advise on signs of abscess (persistent fever, fluctuance) and when to seek urgent care **Key Teaching Message:** "Mastitis is treatable and should not stop you from breastfeeding. Continuing to breastfeed is the best treatment. Your milk is safe for your baby. With antibiotics and frequent feeding, you will improve within a few days. If fever or redness worsens after 2–3 days of antibiotics, return immediately." **Prognosis:** With appropriate antibiotic therapy and continued breastfeeding, the majority of mastitis cases resolve completely within 10–14 days with no long-term complications. Recurrence is possible if risk factors (poor latch, milk stasis, stress) persist; approximately 5–10% of mothers have recurrent mastitis. Prevention through education and early intervention is key.

Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a life-threatening postpartum complication and a leading cause of maternal mortality in developed countries. The postpartum period creates a perfect "storm" for clot formation: pregnancy is a hypercoagulable state, labor causes vessel injury, and postpartum immobility increases venous stasis. Understanding risk factors, clinical presentation, and management is essential for NLE success and clinical safety. **Virchow's Triad and Postpartum VTE Risk:** Virchow's triad describes three conditions promoting thrombosis: 1. **Hypercoagulability:** Pregnancy increases circulating clotting factors (II, VII, VIII, X, XII, XIII) and fibrinogen; decreases protein S (an anticoagulant). This hypercoagulable state persists for 6–12 weeks postpartum. The purpose is evolutionary (to prevent hemorrhage at delivery), but it predisposes to clotting. 2. **Venous stasis:** Labor immobilizes the mother for hours; postpartum bed rest, limited mobility, and dehydration slow venous return in the legs. Compression of the iliac vein by the gravid uterus during pregnancy also impairs flow; this resolves after delivery but leaves the venous system weakened. 3. **Vessel injury:** Placental delivery causes disruption of the endothelium (inner lining) of the uterine vasculature; cesarean delivery causes surgical trauma and additional venous/arteral injury; instrumental vaginal delivery can cause minor vessel injury. All three components are present postpartum, creating high thrombosis risk. **Epidemiology:** - **DVT incidence:** 0.5–3 per 1,000 postpartum women (higher after cesarean) - **PE incidence:** 0.5–2 per 1,000 postpartum women - **Mortality from PE:** If untreated or delayed, mortality can exceed 30%; with prompt anticoagulation, mortality drops to <2% - **Timing:** Most postpartum VTE occurs within the first 2 weeks, but risk remains elevated for 6 weeks or more - **Cesarean delivery increases risk:** 5–10 fold higher than vaginal delivery - **Recurrence:** Women with prior VTE have recurrence risk of 10–15% in subsequent pregnancies/postpartum periods **Risk Factors for Postpartum VTE:** **Obstetric Risk Factors:** - **Cesarean delivery** (especially emergency cesarean and general anesthesia) — the single largest risk factor - **Prolonged labor or bed rest** - **Operative vaginal delivery** (forceps, vacuum) — minor increase in risk - **Preeclampsia or eclampsia** — hemolysis, elevated liver enzymes, low platelets (HELLP) syndrome increases coagulation activation - **Placental abruption** — DIC (disseminated intravascular coagulation) with consumption of anticoagulants - **Amniotic fluid embolism** — rare, catastrophic; triggers DIC - **Postpartum hemorrhage** — transfusion activates coagulation cascade - **Manual removal of placenta** — additional uterine manipulation and tissue trauma **Maternal/Medical Risk Factors:** - **Obesity** (BMI ≥30) — increased inflammatory state, impaired mobility - **Advanced maternal age** (≥35 years) — age-related increased thrombosis risk - **Smoking** — endothelial dysfunction, increased platelet aggregation - **Diabetes mellitus** — endothelial dysfunction - **Hypertension** — endothelial damage - **Prior thrombophilia or family history of VTE** — inherited clotting disorders (Factor V Leiden, prothrombin gene mutation, etc.) - **Active malignancy** — cancer cells produce tissue factor, trigger coagulation - **Thrombophilia (inherited or acquired):** Factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein C/S deficiency, antiphospholipid syndrome - **Immobility or paralysis** — spinal anesthesia complications, bed rest - **Recent surgery** — activation of coagulation cascade - **Cardiac disease** — right-sided heart disease, atrial fibrillation, dilated cardiomyopathy (especially peripartum cardiomyopathy) - **Sepsis or infection** — inflammation triggers coagulation **Clinical Presentation of DVT:** **Unilateral Lower Extremity DVT (Most Common):** DVT classically presents as **one leg affected** (bilateral DVT is rare and suggests more severe thrombosis or IVC involvement). Symptoms typically develop acutely over hours to 1–2 days: **Classic Signs and Symptoms:** - **Leg pain:** sudden onset, may be localized to the calf or extend along the leg; severity varies (mild discomfort to severe pain) - **Leg swelling (edema):** the affected leg is noticeably swollen compared to the other; swelling may be massive in proximal DVT (iliac or femoral veins) - **Warmth:** the affected leg feels warmer than the contralateral leg on palpation - **Erythema (redness):** the skin over the affected area may appear red or dusky; more common in proximal DVT - **Palpable cord:** in some cases, the thrombosed vein feels like a hard cord or rope under the skin (though this is uncommon and not reliable) - **Pain with dorsiflexion (Homan's sign):** calf pain when the foot is passively flexed (pulling toes toward the shin). Historically, this was taught as a classic sign, but **Homan's sign is unreliable and non-specific** (it also occurs with calf muscle injury, cellulitis, and Baker's cyst rupture); modern guidelines de-emphasize its use. Do NOT rely on Homan's sign for diagnosis. **Timeline and Onset:** DVT symptoms typically appear **within the first 2 weeks postpartum**, though they can occur anytime during the 6-week postpartum period or even later. A mother who was walking normally at postpartum day 3 and suddenly develops leg swelling and pain should raise suspicion for DVT. **Types of DVT:** - **Proximal DVT** (popliteal, femoral, iliac veins) — more likely to embolize; associated with more severe symptoms (massive swelling, systemic symptoms) - **Distal DVT** (calf veins only, below the knee) — lower embolization risk; may be asymptomatic - **Superficial Thrombophlebitis** (thrombosis of superficial veins, not DVT proper) — presents as a tender, red, palpable cord along the course of a superficial vein (e.g., saphenous vein); generally benign if no involvement of deeper veins; however, can progress to DVT in some cases **Assessment Findings:** - **Bilateral leg circumference measurement:** measure calf and thigh at standardized points (e.g., 10 cm below the knee, 10 cm above the knee); a difference of >1.3 cm between legs suggests DVT - **Wells DVT Score:** a validated clinical prediction tool assigning points to symptoms and signs; helps estimate pretest probability of DVT - **Compression ultrasound (duplex ultrasound):** the diagnostic gold standard; non-invasive, no radiation, can assess blood flow and visualize clot; sensitivity/specificity >95% for proximal DVT - **D-dimer:** elevated fibrin breakdown product; highly sensitive but non-specific (elevated in many postpartum conditions; not a standalone diagnostic test). Used as a screening tool (very high negative predictive value if normal); if D-dimer is normal, DVT is very unlikely. - **MRI:** reserved for special situations (e.g., suspected IVC thrombosis, pelvic DVT) - **CT pulmonary angiography (CTPA):** if PE is suspected (see below) **Clinical Presentation of Pulmonary Embolism (PE) — A Medical Emergency:** PE occurs when a thrombus (usually from a leg DVT) dislodges, travels through the venous system, and lodges in the pulmonary vasculature, obstructing blood flow to the lungs. PE is the feared complication of DVT and a medical emergency; untreated PE has mortality exceeding 30%. **Risk Factors for PE in Postpartum Woman:** - Prior DVT or PE - Proximal (vs. distal) DVT - Massive PE: large thrombus or multiple emboli **Classic Presentation of PE:** **Sudden onset** of one or more of the following: - **Dyspnea (shortness of breath):** the most common symptom; acute, unexplained dyspnea in a postpartum woman is PE until proven otherwise - **Pleuritic chest pain:** sharp, stabbing pain in the chest that worsens with deep breathing or coughing (suggesting involvement of the pleura); may be unilateral - **Tachypnea (rapid breathing):** respiratory rate >20 breaths/min, often >30 breaths/min in severe PE - **Tachycardia:** heart rate often 110–130 bpm or higher - **Apprehension or anxiety:** mother feels a sense of impending doom or severe anxiety - **Hemoptysis (coughing up blood):** less common; suggests infarction of lung tissue - **Syncope (fainting) or presyncope:** suggests massive PE obstructing a large portion of the pulmonary vasculature - **Cyanosis:** blue discoloration of lips and fingernails in severe hypoxemia **Severity and Presentation Spectrum:** - **Subsegmental or small PE:** may be asymptomatic or present with minimal dyspnea; may be detected incidentally on imaging done for other reasons - **Segmental PE:** presents with dyspnea, chest pain, and tachycardia - **Massive (central) PE:** presents with severe dyspnea, chest pain, hypotension, syncope, and severe hypoxemia; can cause sudden cardiovascular collapse **Differential Diagnosis (Other Causes of Postpartum Dyspnea/Chest Pain):** Postpartum women are at risk for multiple conditions causing dyspnea: - **Pneumonia** — fever, productive cough, infiltrate on chest X-ray - **Myocardial infarction** — chest pain, EKG changes, elevated troponin (rare in young women but can occur with peripartum cardiomyopathy or cocaine use) - **Peripartum cardiomyopathy** — postpartum heart failure, dyspnea, orthopnea, pulmonary edema - **Amniotic fluid embolism** — rare, catastrophic; during delivery or shortly after - **Anxiety or panic attack** — though these do not explain objective findings like tachypnea/hypoxemia - **Pneumothorax** — sudden dyspnea, chest pain; seen on chest X-ray **Key Point:** Any postpartum woman with acute dyspnea and/or pleuritic chest pain must be evaluated urgently for PE; do not assume anxiety or dismiss symptoms. **Assessment Findings in PE:** - **Arterial blood gas (ABG):** hypoxemia (PaO2 <80 mmHg), hypocapnia (PaCO2 <35 mmHg) due to hyperventilation; A-a gradient elevated (normal <10–15; PE often >20) - **Chest X-ray:** may be normal in up to 25% of PE cases; may show wedge-shaped infiltrate (Hampton hump) suggesting pulmonary infarction, or atelectasis - **EKG:** often normal; may show sinus tachycardia, right axis deviation, or (rarely) classic S1Q3T3 pattern (S wave in lead I, Q wave in lead III, T wave inversion in lead III) — but this pattern is uncommon - **D-dimer:** elevated (very sensitive, non-specific); normal D-dimer makes PE unlikely - **Troponin and B-type natriuretic peptide (BNP):** may be elevated if right heart strain is present - **CT pulmonary angiography (CTPA):** the gold standard for PE diagnosis; IV contrast is injected, and the pulmonary arteries are visualized to detect filling defects (thrombi). Sensitivity/specificity >95%. CTPA is the first-line diagnostic test for suspected PE. - **Ventilation-perfusion (V/Q) scan:** an alternative to CTPA if CTPA is contraindicated (e.g., severe contrast allergy); less sensitive than CTPA but useful in specific scenarios - **Echocardiography:** assesses right ventricular function; in massive PE, RV dilatation and dysfunction are seen; helps assess prognosis - **Compression ultrasound of legs:** if DVT is found, it confirms the source of the PE; however, absence of DVT on ultrasound does not rule out PE (DVT may have already embolized or may be in the pelvic veins or upper extremity) **Nursing Diagnosis (NANDA) and Priority Assessment:** Using NANDA-I and Maslow: - **Ineffective tissue perfusion (cardiopulmonary)** — life-threatening; highest priority - **Impaired gas exchange** — related to ventilation-perfusion mismatch; addresses oxygenation and breathing - **Acute pain** (chest/leg pain) — relates to pleural inflammation or calf swelling - **Anxiety** — common response to acute, frightening symptoms - **Risk for bleeding** (if anticoagulated) — safety consideration during treatment - **Deficient Knowledge** — regarding anticoagulation, DVT/PE prevention, signs/symptoms to monitor **Priority Nursing Management:** **For DVT:** **1. Accurate Diagnosis:** - **Perform bilateral leg examination:** - Bilateral leg circumference at standardized points (calf, thigh) - Palpate for warmth, erythema, edema, palpable cord - Assess pain with passive dorsiflexion (Homan's sign — unreliable but note result; do not rely on it) - Assess for Lowenberg sign (calf pain with inflation of a BP cuff to above systolic pressure) — also unreliable; not recommended - Check capillary refill, pulses, skin color in both legs (rule out compartment syndrome or arterial insufficiency) - **Notify provider immediately** if DVT is suspected; compression ultrasound is the definitive diagnostic test **2. Anticoagulation Therapy (as ordered by the obstetrician/provider):** **Anticoagulants Safe in Pregnancy and Lactation:** This is a critical distinction: some anticoagulants cross the placenta and are teratogenic (unsafe in pregnancy); others do not and are safe even if the mother becomes pregnant during treatment. **Heparin (Unfractionated Heparin, UFH):** - **Mechanism:** Direct inhibitor of thrombin; prevents clot formation and growth - **Route:** Intravenous or subcutaneous - **Dosing (for DVT treatment):** Loading dose ~80 units/kg IV bolus; then continuous IV infusion at 18 units/kg/hr, titrated to maintain aPTT 1.5–2.5 times normal (therapeutic range varies by lab) - **Monitoring:** aPTT (activated partial thromboplastin time) — checked at baseline, 6 hours after initiation, then daily. Target aPTT should be therapeutic within 24 hours - **Antidote:** Protamine sulfate (1 mg per 100 units of heparin) — reverses heparin's anticoagulant effect if bleeding occurs - **Advantages in postpartum:** Does NOT cross the placenta; does NOT enter breast milk (heparin is a large, charged molecule); rapidly reversed with protamine; allows rapid control of anticoagulation - **Disadvantages:** Requires continuous IV infusion or frequent SC injections (3–4 times daily); monitoring with aPTT; risk of heparin-induced thrombocytopenia (HIT, ~1–3% incidence; platelet count drops, and paradoxically thrombosis can occur) - **Duration:** Typically given for 5–7 days for DVT; then transition to warfarin or another long-term anticoagulant - **Platelet monitoring:** Check platelet count before heparin initiation and periodically during therapy (watch for HIT) **Low-Molecular-Weight Heparin (LMWH), e.g., Enoxaparin (Lovenox):** - **Mechanism:** Selective anti-Xa activity; similar to UFH but with more predictable pharmacokinetics - **Route:** Subcutaneous injection - **Dosing (for DVT treatment):** Enoxaparin 1 mg/kg SC every 12 hours (or 1.5 mg/kg once daily, though divided dosing is preferred for treatment) - **Monitoring:** Anti-Xa levels (if renal impairment, extreme obesity, or bleeding concerns); less frequently monitored than UFH; aPTT is NOT affected by LMWH - **Antidote:** Protamine sulfate (less effective than for UFH; only partially reverses LMWH, ~60% reversal) - **Advantages:** Subcutaneous injection (no IV line required); once or twice daily dosing; predictable pharmacokinetics; no routine aPTT monitoring; outpatient therapy possible - **Disadvantages:** Slower onset than IV heparin; accumulates in renal impairment; less reversible than UFH - **Duration:** Used for initial treatment (5–7 days) or as bridge therapy until warfarin is therapeutic - **Safety in breastfeeding and pregnancy:** Does NOT cross the placenta; does NOT enter breast milk significantly; safe in both **Warfarin (Coumarin):** - **Mechanism:** Inhibits vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S - **Route:** Oral - **Dosing:** Initial dose ~5 mg orally daily; adjusted based on INR (international normalized ratio) to target INR 2–3 for most VTE - **Monitoring:** INR (measures clotting time relative to normal); checked 3–5 days after initiation, then frequently until stable, then monthly - **Antidote:** Vitamin K (phytonadione) 10 mg IV/oral for significant bleeding; reversal takes 12–24 hours. For immediate reversal, fresh frozen plasma (FFP) or prothrombin complex concentrate (PCC) is used - **Advantages:** Oral administration; long-term treatment once therapeutic; cost-effective - **CRITICAL Disadvantage — TERATOGENIC IN PREGNANCY:** Warfarin crosses the placenta and causes fetal warfarin syndrome (nasal hypoplasia, bone and CNS abnormalities) especially in the first trimester. It is CONTRAINDICATED in pregnant women and women planning pregnancy. - **Safety in breastfeeding:** Warfarin does NOT enter breast milk in clinically significant amounts; it is safe during lactation - **Timeline:** Warfarin requires 5–7 days to achieve therapeutic INR; therefore, it is NOT used for acute DVT or PE. Heparin or LMWH is used first ("bridge therapy"), and once warfarin's INR is therapeutic, heparin is discontinued. - **Duration:** Typically 3–6 months or longer depending on type of VTE and presence of ongoing risk factors **New Oral Anticoagulants (DOACs, e.g., Apixaban, Rivaroxaban):** - **Mechanism:** Direct Xa inhibitors or direct thrombin inhibitors - **Examples:** Rivaroxaban (Xarelto), apixaban (Eliquid), dabigatran (Pradaxa) - **Advantages:** Oral administration; predictable pharmacokinetics; no monitoring required (in most cases) - **Disadvantages for postpartum use:** Limited experience in lactation; some concern about use immediately postpartum (particularly with high bleeding risk). Generally avoided in the acute postpartum period but may be used later - **Warfarin remains the standard for long-term postpartum anticoagulation** after acute phase is stabilized **Anticoagulation Strategy in Postpartum DVT/PE:** 1. **Acute phase (first 5–7 days):** IV heparin or SC LMWH (enoxaparin) - Immediate anticoagulation; no delay for oral drug absorption - Rapid reversal if bleeding (protamine for heparin) - Allows assessment of bleeding risk (especially important postpartum where hemorrhage is a concurrent concern) 2. **Transition phase (days 5–7 onward):** Initiate warfarin; overlap heparin/LMWH until INR is therapeutic (2–3) for ≥24 hours, then discontinue heparin - Warfarin takes 5–7 days to become therapeutic - Overlap prevents transient hypercoagulability (warfarin initially depletes protein C and S faster than factors II, IX, X, leading to paradoxical thrombosis if used alone) 3. **Long-term (weeks to months):** Continue warfarin for 3–6 months (or longer if recurrent VTE, thrombophilia, or malignancy) - Target INR 2–3 - Monitor INR regularly; adjust warfarin dose based on INR **3. General Comfort and Supportive Care for DVT:** - **Bed rest (relative):** Initially, rest the affected leg to reduce pain and edema. Not absolute strict bed rest (which increases VTE risk); rather, modified activity with leg elevation - **Leg elevation:** Elevate the affected leg above the level of the heart (use pillows); promotes venous return and reduces edema - **Warm compresses:** Apply warm, moist compress to the affected calf/leg for 15–20 minutes several times daily; promotes comfort and circulation (though heat does not "dissolve" the clot; warmth is purely symptomatic) - **Compression stockings:** Some sources recommend compression stockings (e.g., graduated compression) to reduce swelling; evidence for efficacy in preventing post-thrombotic syndrome is emerging - **Pain management:** Analgesics as needed (acetaminophen or NSAIDs, though NSAIDs may have some mild antiplatelet effects); severe pain controlled with opioids if needed - **Hydration:** Maintain adequate fluid intake; dehydration increases VTE risk - **Progressive mobilization:** As anticoagulation is established and pain decreases, gradually increase activity; early mobilization prevents complications and improves psychological well-being **CRITICAL:** Do NOT massage the leg; massage can dislodge the thrombus and precipitate PE — a medical emergency. **4. Monitoring During Anticoagulation:** - **Baseline labs before heparin:** CBC (platelet count for HIT baseline), INR, aPTT, renal function, liver function - **Platelet count monitoring:** Check at heparin initiation and day 3–5 during heparin therapy (watch for HIT; platelet count drop ≥50% or fall below 100,000 is concerning) - **aPTT monitoring (if on heparin):** After loading dose, check at 6 hours and 12 hours; then daily while on heparin. Goal aPTT 1.5–2.5 times control - **INR monitoring (if on warfarin):** Baseline INR, then check every 3–5 days until therapeutic, then weekly for 2 weeks, then every 2–4 weeks (or per facility protocol) - **Hemoglobin/hematocrit:** Monitor for bleeding-related anemia; baseline and periodically during anticoagulation - **Signs of bleeding:** Assess for bruising, petechiae, hematuria, melena, hematochezia, epistaxis; if bleeding occurs, notify provider - **Signs of HIT (if on heparin):** thrombosis (paradoxical), thrombocytopenia, skin necrosis at injection sites; if suspected, discontinue heparin immediately and consider alternative anticoagulant **For PE (Medical Emergency):** **1. Immediate Assessment and Stabilization:** PE is a **medical emergency requiring urgent action.** - **Call for immediate help:** Notify the obstetrician, intensivist, and respiratory therapy immediately - **Oxygen therapy:** Apply high-concentration oxygen immediately; target oxygen saturation ≥94–95% (use non-rebreather mask at 8–10 L/min if severe hypoxemia). Monitor with continuous pulse oximetry - **Position:** Semi-Fowler or upright position to promote chest expansion and oxygenation; sitting upright is often better tolerated - **IV access:** Establish large-bore IV access if not already present; prepare for rapid medication/fluid administration - **Continuous cardiac monitoring:** Monitor heart rate and rhythm; watch for arrhythmias (tachycardia is expected; maintain vigilance for atrial fibrillation or other dysrhythmias) - **Vital signs:** Measure BP, HR, RR, temperature, O2 saturation every 5–15 minutes during acute phase - **Assess mental status:** Restlessness, confusion, or anxiety can indicate hypoxemia or shock; address oxygen/perfusion urgently **2. Diagnostic Confirmation:** - **Stat CTPA (CT pulmonary angiography):** Gold standard; confirms PE diagnosis; identifies location and extent of thrombi - **Compression ultrasound of legs:** If already done (from DVT evaluation), confirms source; if not done, can be done simultaneously to look for DVT - **EKG:** Assess for arrhythmias; may show sinus tachycardia or right axis deviation - **Troponin and BNP:** Assess myocardial stress - **ABG (if available):** Assess hypoxemia, hypocapnia, A-a gradient - **D-dimer:** If done, elevated D-dimer supports PE diagnosis (though non-specific); normal D-dimer is reassuring **3. Anticoagulation for PE:** **Acute Phase (First 5–7 Days):** Start **IV heparin immediately** (do not wait for CTPA confirmation if clinical suspicion is high and there is no absolute contraindication to anticoagulation, though confirmation is preferred): - **Loading dose:** Heparin 80 units/kg IV bolus (~5,000–10,000 units for adult) - **Continuous infusion:** 18 units/kg/hr, titrated to aPTT 1.5–2.5 times control - **Rationale for IV heparin over LMWH in acute PE:** IV heparin allows rapid anticoagulation and rapid reversal (protamine) if bleeding occurs; particularly important in postpartum women at risk for hemorrhage Alternatively, **LMWH can be used if IV heparin is unavailable:** - Enoxaparin 1 mg/kg SC every 12 hours **Transition Phase (Days 5–7 Onward):** - Initiate oral warfarin (goal INR 2–3) - Continue heparin/LMWH overlap until INR is therapeutic ≥24 hours - Discontinue heparin once warfarin INR is therapeutic **Long-term Phase (Weeks to Months):** - Warfarin 3–6 months or longer (depends on circumstances; if massive PE or with thrombophilia, longer duration may be needed) **4. Advanced Interventions for Massive PE (Rare, Hemodynamically Unstable):** If the mother develops severe hypoxemia, hypotension, syncope, or cardiac collapse (signs of massive PE with hemodynamic compromise), advanced interventions may be considered: - **Thrombolysis (tissue plasminogen activator, tPA):** Dissolves the thrombus directly; used in massive PE with hemodynamic instability. Risks include major bleeding, including obstetric bleeding (reason for careful consideration in immediate postpartum setting) - **Mechanical thrombectomy:** Catheter-based removal of the thrombus; considered in massive PE if tPA contraindicated or failed - **Supportive measures for shock:** IV fluids (cautious, as pulmonary edema risk exists), vasopressors (dopamine, norepinephrine) to maintain perfusion These interventions are typically managed in an ICU setting; the obstetric team consults with intensivists/pulmonologists. **5. Supportive Care for PE:** - **Oxygen and positioning:** Maintain high-concentration oxygen; semi-Fowler or upright position - **Anxiety management:** The mother is frightened; reassurance, presence of family, and (if needed) anxiolytics help. Explain that treatment is working and recovery is expected - **Pain management:** Analgesics for pleuritic pain; balance with monitoring for respiratory depression (avoid opioids if mild-to-moderate pain; use acetaminophen/NSAIDs first) - **Monitoring and reassurance:** Frequent vital signs, O2 saturation, lung sounds; reassurance that treatment is proceeding - **Restricted activity:** Bed rest initially; as anticoagulation is established and symptoms improve, gradual mobilization **6. Patient Education and Discharge Planning for DVT/PE:** - **Warfarin education (if prescribed for long-term):** - Consistency in vitamin K intake (found in leafy greens) — not avoidance, but consistency day-to-day - Importance of INR monitoring; keep appointments - Signs of bleeding: bruising, blood in urine/stool, nosebleed; report immediately - Medications/supplements that interact with warfarin (aspirin, NSAIDs, antibiotics, herbal products); check with provider before adding any medication - Avoid alcohol excess (increases bleeding risk) - Wear medical alert bracelet/necklace indicating anticoagulation - Inform all providers (dental, surgical) that she is anticoagulated - **Prevention of recurrence:** - Maintain adequate hydration (8–10 glasses water daily) - Avoid prolonged immobility; move legs regularly, change positions, walk - Avoid tight clothing that restricts leg circulation - Use compression stockings if recommended - Weight management (obesity increases VTE risk) - Smoking cessation if applicable - Future pregnancies: inform obstetric provider of prior VTE; anticoagulation may be needed during pregnancy and postpartum in future pregnancies - **When to seek urgent care:** - Sudden dyspnea, chest pain, hemoptysis (signs of PE) - Sudden increase in leg swelling/pain (signs of DVT extension) - Signs of bleeding: heavy vaginal bleeding, blood in urine/stool, severe bruising, hemoptysis - Signs of HIT (if on heparin): unusual bruising, thrombosis symptoms - **Prognosis:** With appropriate anticoagulation, >90% of DVT resolve without long-term complications. PE mortality is <2% with prompt treatment; without treatment, >30%. Encourage adherence to anticoagulation therapy; it is life-saving. **Prevention of Postpartum VTE — A Nursing Priority:** Prevention is preferable to treatment. All postpartum women should receive VTE prophylaxis based on risk assessment. Strategies include: 1. **Early ambulation:** Encourage the mother to get up and walk within hours of delivery (if stable); walking promotes leg muscle contraction and venous return 2. **Leg exercises:** Calf raises, foot pumps (flex and point toes), leg lifts — performed regularly throughout the postpartum period 3. **Hydration:** Adequate fluid intake (2–3 liters/day); avoid dehydration 4. **Graduated compression stockings:** For high-risk women (obesity, immobility, prior VTE) 5. **Sequential compression devices (SCDs):** Mechanical pumps that intermittently inflate around the leg; used in high-risk women or those with absolute contraindication to anticoagulation 6. **Pharmacologic prophylaxis:** For very high-risk women (especially after cesarean with additional risk factors): - **Enoxaparin 40 mg SC once daily** or **unfractionated heparin 5,000 units SC TID** for 7–10 days postpartum; safe in lactation - Must balance VTE prevention against postpartum hemorrhage risk The obstetrician determines if pharmacologic prophylaxis is needed based on ACOG guidelines and individual risk factors.